At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 276 enrolled
Drug / intervention
[18F]Flutemetamoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images.
In Brief
A Phase 3 clinical trial evaluating [18F]Flutemetamol for Alzheimer's Disease and Mild Cognitive Impairment. Completed, enrolled 276 participants.
Detailed Summary
To Evaluate the Effectiveness of an Electronic Training Program for Orienting and Interpreting \[18F\]flutemetamol Positron Emission Tomography (PET) Images.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease, Mild Cognitive Impairment
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
Primary CompletionAug 2012
First PostedAug 2012
TodayJul 2026
First PostedAug 27, 2012
Enrollment StartJul 1, 2012
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 13.8 years ago
Interventions
[18F]Flutemetamoldrug
No drug is administered in this intervention. These are scanned images being reviewed, previously acquired in various GE-067 studies.